Anlotinib
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Anlotinib is one of 661 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.
33
Indications
168
Total Trials
49
Active Trials
660
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer17 trials
Show 14 more trials
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04211896·70 enrolled
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer
Not yet recruiting·—·Phase 2·NCT06221462·30 enrolled
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04453423·90 enrolled
Anlotinib15 trials
Show 12 more trials
Breast Cancer9 trials
Show 6 more trials
Small Cell Lung Cancer8 trials
Show 5 more trials
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07172412·165 enrolled
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruiting·—·Phase 4·NCT06951841·31 enrolled
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruiting·—·Phase 2·NCT07376499·31 enrolled
Soft Tissue Sarcoma7 trials
Show 4 more trials
Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT03792542·44 enrolled
72 more indications
Lung Cancer6 trials
Show 3 more trials
Hepatocellular Carcinoma5 trials
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT03766776·40 enrolled
Thyroid Cancer5 trials
First-line Treatment4 trials
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT04797806·206 enrolled
Brain Metastases3 trials
Nasopharyngeal Carcinoma3 trials
Neoadjuvant Therapy3 trials
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06699498·45 enrolled
Renal Cell Carcinoma3 trials
Ovarian Cancer3 trials
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT03924882·30 enrolled
Glioblastoma3 trials
Advanced Solid Tumors2 trials
Metastatic Colorectal Cancer2 trials
Triple-Negative Breast Cancer2 trials
Non-squamous NSCLC2 trials
Adenocarcinoma2 trials
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03591666·51 enrolled
Pancreatic Cancer2 trials
Glioma2 trials
Esophageal Squamous Cell Carcinoma2 trials
Lung Adenocarcinoma2 trials
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT03728374·38 enrolled
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
Not yet recruiting·—·Phase 2·NCT06483672·27 enrolled
Melanoma2 trials
Treatment2 trials
Esophageal Cancer2 trials
Anlotinib for Esophageal Cancer (AFEC)
Unknown status·—··NCT04966611·200 enrolled
Lymphoma1 trial
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
Completed·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT03618238·20 enrolled
Urothelial Carcinoma1 trial
Second-line Treatment1 trial
Adverse Reaction1 trial
Advanced Renal Cancer1 trial
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolledOvarian Clear Cell Carcinoma1 trial
Paclitaxel1 trial
Pancreatic Neoplasm1 trial
Gastrointestinal Stromal Tumor1 trial
Advanced NSCLC1 trial
Endometrial Cancer1 trial
Intestinal Cancer1 trial
First Line Therapy1 trial
Metastatic Melanoma1 trial
Patients With Advanced Solid Tumors1 trial
Maintenance Therapy1 trial
Efficacy and Safety1 trial
Sacituzumab Tirumotecan1 trial
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
Not yet recruiting·—·Phase 2·NCT07388875·30 enrolled
Maintenance Treatment1 trial
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT03769805·83 enrolled
Cholangiocarcinoma1 trial
Craniopharyngioma1 trial
Advanced Solid Tumor1 trial
Esophageal Squamous Cell Cancer1 trial
Advanced Cancer1 trial
Whole-Brain Radiotherapy1 trial
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Recruiting·—·Phase 3·NCT07443397·134 enrolled
Carboplatin1 trial
Biliary Tract Cancer1 trial
Desmoid Tumor1 trial
Refractory1 trial
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
Terminated·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT04232397·5 enrolled
Refractory Solid Tumors1 trial
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Not yet recruiting·—·Phase 2·NCT06761417·49 enrolled
Concurrent Chemoradiotherapy1 trial
Tolerance1 trial
Undifferentiated Pleomorphic Sarcoma1 trial
Paraganglioma1 trial
Gastrointestinal Tumors1 trial
Pancreatic Neuroendocrine Tumor1 trial
Non-Small Cell Lung Carcinoma1 trial
NSCLC (Advanced Non-small Cell Lung Cancer)1 trial
A Multicenter Clinical Study Evaluating the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Anlotinib as Second-Line Treatment for Patients With Driver Gene-Negative Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Active, not recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT07703228·38 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anlotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details